Pfizer will be reducing its U.S. sales staff as it expects doctors and other healthcare providers to want fewer face-to-face interactions with sales people, Reuters news report said.
The move comes as the company is expected to announce more than $80 billion in revenue in 2021 on strong sales of the COVID-19 vaccine it developed with Germany’s BioNTech SE . That would be record sales for a pharmaceutical company, according to Pfizer Chief Executive Albert Bourla.
